BR112017028530A2 - terapia combinada para tratamento de cânceres hematológicos e tumores sólidos - Google Patents

terapia combinada para tratamento de cânceres hematológicos e tumores sólidos

Info

Publication number
BR112017028530A2
BR112017028530A2 BR112017028530A BR112017028530A BR112017028530A2 BR 112017028530 A2 BR112017028530 A2 BR 112017028530A2 BR 112017028530 A BR112017028530 A BR 112017028530A BR 112017028530 A BR112017028530 A BR 112017028530A BR 112017028530 A2 BR112017028530 A2 BR 112017028530A2
Authority
BR
Brazil
Prior art keywords
combination therapy
solid tumors
treatment
haematological cancers
cancers
Prior art date
Application number
BR112017028530A
Other languages
English (en)
Portuguese (pt)
Inventor
Gandhi Anita
CHIU Hsiling
POURDEHNAD Michael
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112017028530A2 publication Critical patent/BR112017028530A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017028530A 2015-07-02 2016-07-01 terapia combinada para tratamento de cânceres hematológicos e tumores sólidos BR112017028530A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562188404P 2015-07-02 2015-07-02
US201562245916P 2015-10-23 2015-10-23
US201662308055P 2016-03-14 2016-03-14
US201662340972P 2016-05-24 2016-05-24
PCT/US2016/040718 WO2017004532A1 (en) 2015-07-02 2016-07-01 Combination therapy for treatment of hematological cancers and solid tumors

Publications (1)

Publication Number Publication Date
BR112017028530A2 true BR112017028530A2 (pt) 2018-08-28

Family

ID=56418624

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028530A BR112017028530A2 (pt) 2015-07-02 2016-07-01 terapia combinada para tratamento de cânceres hematológicos e tumores sólidos

Country Status (10)

Country Link
US (1) US10973822B2 (https=)
EP (1) EP3316888A1 (https=)
JP (2) JP6727237B2 (https=)
KR (1) KR20180023968A (https=)
AU (1) AU2016288246A1 (https=)
BR (1) BR112017028530A2 (https=)
CA (1) CA2991164A1 (https=)
EA (1) EA201890199A1 (https=)
MX (1) MX2018000216A (https=)
WO (1) WO2017004532A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070606A1 (en) 2015-10-21 2017-04-27 Teclison Limited Compositions and methods for immune-mediated cancer therapy
CA3006758A1 (en) 2015-12-02 2017-06-08 Celgene Corporation Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
CN110678200B (zh) 2017-05-30 2024-05-17 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
US12064436B2 (en) 2017-06-12 2024-08-20 Servier Pharmaceuticals Llc Methods of treating brain tumors using combination therapy
CA3067035A1 (en) 2017-06-12 2018-12-20 Agios Pharmaceuticals, Inc. Methods of treating brain tumors using combination therapy
MX2020003395A (es) * 2017-10-13 2020-08-03 Merck Sharp & Dohme Composiciones y metodos para tratar linfoma difuso de celulas b grandes.
US20230132400A9 (en) * 2017-11-10 2023-04-27 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
CA3107186A1 (en) * 2018-07-30 2020-02-06 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
EP3974455A4 (en) * 2019-05-21 2023-06-14 Kuraray Noritake Dental Inc. RESIN COMPOSITION FOR OPTICAL THREE-DIMENSIONAL MODELING
WO2021041669A1 (en) * 2019-08-30 2021-03-04 Dana-Farber Cancer Institute, Inc. Immune signatures predictive of response to pd-1 blockade in richter's transformation
US11839619B2 (en) * 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis
WO2021092190A1 (en) * 2019-11-05 2021-05-14 Health Research, Inc. Combination therapy for cancer
EP4073517A1 (en) * 2019-12-11 2022-10-19 Erasmus University Rotterdam Medical Center Method for monitoring of deep remissions in multiple myeloma and other plasma cell dyscrasias
US20220117929A1 (en) * 2020-10-21 2022-04-21 Buddhist Tzu Chi Medical Foundation Method for preventing or treating high-grade serous carcinoma
US12523658B2 (en) * 2021-08-27 2026-01-13 The Board Of Regents Of The University Of Texas System Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications
CA3224890A1 (en) * 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
CN115137731B (zh) * 2022-05-19 2023-11-21 上海交通大学医学院附属新华医院 Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
ME02420B (me) 2006-09-26 2016-09-20 Celgene Corp 5-supstituirani derivati kinazolinona kao sredstva protiv raka
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
CA2704710C (en) 2007-09-26 2016-02-02 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
PH12013501837A1 (en) * 2011-03-11 2013-11-18 Celgene Corp Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
EP2892887B1 (en) 2012-09-04 2020-07-15 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
EP2892537A1 (en) * 2012-09-10 2015-07-15 Celgene Corporation Methods for the treatment of locally advanced breast cancer
JP6359563B2 (ja) 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
SMT201700513T1 (it) 2013-05-01 2018-01-11 Celgene Corp Sintesi di 3-(5-ammino-2-metil-4-ossochinazolin-3(4h)-il) piperidin-2,6-dione
EP2991651A1 (en) * 2013-05-03 2016-03-09 Celgene Corporation Methods for treating cancer using combination therapy
IL292510A (en) * 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
TW201540323A (zh) 2014-01-15 2015-11-01 Celgene Corp ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物
KR20170029565A (ko) 2014-07-11 2017-03-15 셀진 코포레이션 암 치료를 위한 병용요법
CA2996641A1 (en) 2015-08-27 2017-03-02 Celgene Corporation Pharmaceutical compositions comprising 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
CA3006758A1 (en) 2015-12-02 2017-06-08 Celgene Corporation Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Also Published As

Publication number Publication date
JP2018524347A (ja) 2018-08-30
JP2020172502A (ja) 2020-10-22
KR20180023968A (ko) 2018-03-07
EP3316888A1 (en) 2018-05-09
WO2017004532A1 (en) 2017-01-05
US20180193342A1 (en) 2018-07-12
EA201890199A1 (ru) 2018-06-29
JP6727237B2 (ja) 2020-07-22
AU2016288246A1 (en) 2018-02-01
MX2018000216A (es) 2018-05-22
US10973822B2 (en) 2021-04-13
CA2991164A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
BR112017028530A2 (pt) terapia combinada para tratamento de cânceres hematológicos e tumores sólidos
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
BR112016005303A2 (pt) anticorpos anti-b7-h1 para tratamento de tumores
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
EA201591509A1 (ru) Ингибиторы cdc7
PL3426271T3 (pl) Sposoby leczenia guzów litych terapią skojarzoną
MX2022008868A (es) Tratamiento del cancer con tg02.
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
EA201300171A1 (ru) Способы и композиции для терапии рака печени
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
EA201700464A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
EP4691562A3 (en) Anti-pd-l1 combinations for treating tumors
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
IL290011A (en) Ezh2 inhibition in combination therapies for the treatment of cancers
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]